UNSPSC 51313501: Isocromil

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0L7AR6G18O. European Medicines Agency schedules Isocromil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08315MIG. Isocromil generally arises in the molecular formula C19H16O5. The term ISOCROMIL is an International Non-Proprietary Name or INN. ISOCROMIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule isocromil under HS 29329985 and SITC 51569. As of Q4 2014, ISOCROMIL remains the US FDA Preferred Term for this commodity. Isocromil bears US NLM identifiers UMLS ID C1881276 and NCI Concept Code C65973. SMILES: O(C(C)C)C1C(OC(=O)C2CC3C(OCCC3=O)CC2)CCCC1.

UNSPSC 51313501 Isocromil (Commodity) covers pharmaceutical products and related health-service supplies procured by state and local governments, though recent activity under this specific code reflects a broader pattern of state and county procurement of pharmaceutical inventory, naloxone and drug-deactivation systems, and generic multi-source medications for public health and employee benefit programs. State and local solicitations under this code span county health departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Issuing bodies include county governments and state departments of health and human services, working either independently or through statewide cooperative purchasing vehicles to consolidate procurement and negotiate volume pricing.

Recent opportunities show activity across Florida and Minnesota, with Texas state agencies conducting market research on pharmacy benefit models. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a response deadline of July 26, 2023 and contract terms of two years plus one optional renewal year; the procurement required E-Verify compliance and specified workers' compensation and general liability insurance. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and awarded products effective July 1, 2026; evaluation weighted price competitiveness at 75 percent and required vendors to maintain relationships with authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs as a preliminary information-gathering phase before formal competitive solicitation.